Elotuzumab
Reading tools
Elotuzumab (Empliciti®), which received FDA approval on 30 November 2015, is used in previously treated patients with multiple myeloma, together with the drugs called Lenalidomide and Dexamethasone. Like Daratumumab, Elotuzumab is an immunotherapeutic (immune system-regulating) drug and targets the protein called SLAMF7 found both on multiple myeloma cells and on natural killer cells. In this way, it enables Natural Killer cells, a component of the defense system, to attack and destroy cancer cells.
The most common side effects of Elotuzumab are fatigue, diarrhea, high fever, constipation and cough.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.